APUS

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Index	-	P/E	-	EPS (ttm)	-0.32	Insider Own	82.00%	Shs Outstand	12.58M	Perf Week	10.61%
Market Cap	27.55M	Forward P/E	-	EPS next Y	-	Insider Trans	5.70%	Shs Float	2.26M	Perf Month	27.33%
Enterprise Value	19.31M	PEG	-	EPS next Q	-	Inst Own	0.23%	Short Float	1.84%	Perf Quarter	38.61%
Income	-3.71M	P/S	-	EPS this Y	-	Inst Trans	6.41%	Short Ratio	0.37	Perf Half Y	-
Sales	0.00M	P/B	2.83	EPS next Y	-	ROA	-69.84%	Short Interest	0.04M	Perf YTD	-0.45%
Book/sh	0.77	P/C	3.15	EPS next 5Y	-	ROE	-82.20%	52W High	4.00 -45.25%	Perf Year	-
Cash/sh	0.69	P/FCF	-	EPS past 3/5Y	-50.14% -	ROIC	-38.09%	52W Low	1.37 59.85%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.48% 7.67%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-181.36%	Oper. Margin	-	ATR (14)	0.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.79	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	63.64	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	12.79	EPS Q/Q	-498.02%	SMA20	15.85%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	15.51%	Rel Volume	1.36	Prev Close	2.04
Employees	2	LT Debt/Eq	0.00	Earnings	-	SMA200	18.89%	Avg Volume	113.02K	Price	2.19
IPO	May 09, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	154,138	Change	7.35%

Oct-14-25 03:02AM	Apimeds Pharmaceuticals says I love my Ducks with new ai Futures Lab Program collaboration with the University of Oregons Lundquist College of Business (Business Wire)
Sep-11-25 09:54PM	Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program (Business Wire) +7.22%
Jul-15-25 05:34PM	Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division (Business Wire)
May-12-25 05:14PM	Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering (GlobeNewswire) -17.73%
May-08-25 05:00PM	Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering (GlobeNewswire)

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. It primarily focuses on developing innovative therapies for inflammation and pain management in knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS). The company was founded on May 11, 2020 and is headquartered in Matawan, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kim Christopher	Chairman and CMO	May 13 '25	Buy	1.82	19,770	35,981	19,770	May 15 06:48 PM
Kim Christopher	Chairman and CMO	May 14 '25	Buy	1.86	7,730	14,378	27,500	May 15 06:48 PM
Koo Jakap	Director	May 12 '25	Buy	1.99	28,500	56,715	643,885	May 14 05:58 PM
Inscobee Inc.	10% Owner	May 12 '25	Buy	4.00	500,000	2,000,000	1,984,616	May 14 05:52 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Apimeds Pharmaceuticals US Inc

Upgrade your FINVIZ experience